Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
Ghezzi A, Bianchi A, Baroncini D, Bertolotto A, Malucchi S, Bresciamorra V, Lanzillo R, Milani N, Martinelli V, Patti F, Chisari C, Rottoli M, Simone M, Paolicelli D, Visconti A; FUTURE Study Group. Ghezzi A, et al. Among authors: martinelli v. Neurol Sci. 2017 Nov;38(11):1999-2005. doi: 10.1007/s10072-017-3091-6. Epub 2017 Aug 22. Neurol Sci. 2017. PMID: 28831635
Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Ghezzi A, et al. Among authors: martinelli v. Neurol Sci. 2007 Jun;28(3):127-32. doi: 10.1007/s10072-007-0804-2. Epub 2007 Jun 30. Neurol Sci. 2007. PMID: 17603763 Clinical Trial.
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, Marrosu MG, Martinelli V, Milani N, Moiola L, Patti F, Pozzilli C, Trojano M, Zaffaroni M, Comi G; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Ghezzi A, et al. Among authors: martinelli v. Neurol Sci. 2009 Jun;30(3):193-9. doi: 10.1007/s10072-009-0083-1. Epub 2009 Apr 22. Neurol Sci. 2009. PMID: 19387545 Clinical Trial.
The prognosis of idiopathic optic neuritis.
Ghezzi A, Martinelli V, Rodegher M, Zaffaroni M, Comi G. Ghezzi A, et al. Among authors: martinelli v. Neurol Sci. 2000;21(4 Suppl 2):S865-9. doi: 10.1007/s100720070028. Neurol Sci. 2000. PMID: 11205365
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, Milani N, Milanese C, Moiola L, Patti F, Pilato V, Pozzilli C, Trojano M, Zaffaroni M, Comi G; Immunomodulatory Treatment of Early onset MS Group. Ghezzi A, et al. Among authors: martinelli v. Mult Scler. 2005 Aug;11(4):420-4. doi: 10.1191/1352458505ms1206oa. Mult Scler. 2005. PMID: 16042224 Clinical Trial.
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy.
Loraschi A, Bellantonio P, Bortolon F, Capra R, Cavalla P, Costantino G, Lugaresi A, Martinelli V, Marrosu MG, Patti F, Rottoli M, Salvetti M, Sola P, Solaro C, Klersy C, Marino F, Zaffaroni M, Cosentino M. Loraschi A, et al. Among authors: martinelli v. Neurol Sci. 2016 Apr;37(4):613-22. doi: 10.1007/s10072-016-2519-8. Epub 2016 Feb 19. Neurol Sci. 2016. PMID: 26895323
Prognosis-modifying therapy in multiple sclerosis.
Comi G, Colombo B, Martinelli V. Comi G, et al. Among authors: martinelli v. Neurol Sci. 2000;21(4 Suppl 2):S893-9. doi: 10.1007/s100720070033. Neurol Sci. 2000. PMID: 11205370 Review.
598 results